Status:

ACTIVE_NOT_RECRUITING

Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Head and Neck Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The goal of this research study is to learn if home-use of devices to identify dehydration risk, when added to standard care, will help to lower hospitalizations and emergency room visits (and related...

Detailed Description

Abstract: While head and neck cancer (HNC) is highly curable, primary radiation treatment (RT) is nonetheless challenging. Despite intensive, high-quality, multidisciplinary symptom management of HNC...

Eligibility Criteria

Inclusion

  • Diagnosis of any of the following cancers: stage 1-4b (includes 4a) oropharyngeal, hypopharyngeal, nasopharyngeal, salivary gland or oral cavity; stage 3-4b (includes 4a) laryngeal; any unknown primary head and neck cancer with cervical metastasis that will be addressed with treatment to bilateral necks and mucosa; any thyroid cancer that will be addressed with treatment to the bilateral necks; or other head and neck cancers medically approved by one of our Radiation Oncology collaborating MDs
  • Currently receiving (or scheduled to receive) radiation treatment for a cancer listed in the inclusion criteria
  • Age 18 years or older
  • Fluent in English
  • Radiation treatment for this cancer was completed (or will be completed) at MD Anderson Cancer Center (Post-RT study only)
  • Receiving radiation treatment for this cancer at any site within the MDACC Cancer Network (Cancer Network study only)

Exclusion

  • Overt cognitive difficulty demonstrated by not being clearly oriented to person or place or time
  • Zubrod Performance Status \>2, or self-reports either not being up and about more than 50% of waking hours or unable to provide self-care
  • History of current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g. dysphagia due to underlying neurogenic disorder)
  • Orthopedic, neurologic, or musculoskeletal disability that would interfere with the functional task of standing on a weight scale
  • Scheduled to receive or receiving unilateral radiation treatment for this cancer
  • Received previous radiation treatment for head and neck cancer
  • Consented to enroll in a trial with a toxicity endpoint
  • Undergoing only palliative (not curative) radiation treatment

Key Trial Info

Start Date :

January 7 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 30 2027

Estimated Enrollment :

427 Patients enrolled

Trial Details

Trial ID

NCT02253238

Start Date

January 7 2014

End Date

April 30 2027

Last Update

November 6 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030